Literature DB >> 30252681

Clinical Outcome After Rectal Replacement With Side-to-End, Colon-J-Pouch, or Straight Colorectal Anastomosis Following Total Mesorectal Excision: A Swiss Prospective, Randomized, Multicenter Trial (SAKK 40/04).

Walter R Marti1, Gaudenz Curti1, Heinz Wehrli2, Felix Grieder3, Michael Graf4, Beat Gloor5, Markus Zuber6, Nicolas Demartines7, Fabrizio Fasolini8, Bruno Lerf9, Christoph Kettelhack10, Christiane Andrieu11, Martin Bigler11, Stefanie Hayoz11, Karin Ribi11, Christian Hamel12.   

Abstract

OBJECTIVE: To compare, in a phase 3, prospective, randomized, multi-center clinical trial functional outcome of reconstruction procedures following total mesorectal excision (TME). SUMMARY BACKGROUND DATA: Intestinal continuity reconstruction following TME is accompanied by postoperative defecation dysfunctions known as "anterior resection syndrome." Commonly used reconstruction techniques are straight colorectal anastomosis (SCA), colon J -pouch (CJP), and side-to-end anastomosis (SEA). Comparison of their functional outcomes in prospective, randomized, multi-center studies, including long-term assessments, is lacking.
METHODS: Patients requiring TME for histologically proven rectal tumor, with or without neoadjuvant treatment, age ≥ 18 years, normal sphincter function without history of incontinence, any pretreatment staging or adenoma, expected R0-resection, were randomized for standardized SCA, CJP, or SEA procedures. Primary endpoint was comparison of composite evacuation scores 12 months after TME. Comparison of composite evacuation and incontinence scores at 6, 18 and 24 months after surgery, morbidity, and overall survival represented secondary endpoints. Analysis was based on "per protocol" (PP) population, fully complying with trial requirements, and intention-to treat (ITT) population.
RESULTS: Three hundred thirty-six patients from 15 hospitals were randomized. PP population included 257 patients (JCP = 63; SEA = 95; SCA = 99). Composite evacuation scores of PP and ITT populations did not show statistically significant differences among the 3 groups at any time point. Similarly, composite incontinence scores for PP and ITT populations showed no statistically significant difference among the 3 trial arms at any time point.
CONCLUSIONS: Within boundaries of investigated procedures, surgeons in charge may continue to perform reconstruction of intestinal continuity following TME at their technical preference.

Entities:  

Year:  2019        PMID: 30252681     DOI: 10.1097/SLA.0000000000003057

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  5 in total

Review 1.  The incidence and risk factors of low anterior resection syndrome (LARS) after sphincter-preserving surgery of rectal cancer: a systematic review and meta-analysis.

Authors:  Rui Sun; Ziyi Dai; Yin Zhang; Junyang Lu; Yuelun Zhang; Yi Xiao
Journal:  Support Care Cancer       Date:  2021-07-23       Impact factor: 3.603

Review 2.  Defining Anastomotic Leak and the Clinical Relevance of Leaks.

Authors:  Clayton Tyler Ellis; Justin A Maykel
Journal:  Clin Colon Rectal Surg       Date:  2021-10-01

3.  Impact of the novel powered circular stapler on risk of anastomotic leakage in colorectal anastomosis: a propensity score-matched study.

Authors:  V Pla-Martí; J Martín-Arévalo; D Moro-Valdezate; S García-Botello; I Mora-Oliver; R Gadea-Mateo; C Cozar-Lozano; A Espí-Macías
Journal:  Tech Coloproctol       Date:  2020-09-10       Impact factor: 3.781

Review 4.  Safety and efficacy of side-to-end anastomosis versus colonic J-pouch anastomosis in sphincter-preserving resections: an updated meta-analysis of randomized controlled trials.

Authors:  Sen Hou; Quan Wang; Shidong Zhao; Fan Liu; Peng Guo; Yingjiang Ye
Journal:  World J Surg Oncol       Date:  2021-04-21       Impact factor: 2.754

Review 5.  Ultimate Functional Preservation With Intersphincteric Resection for Rectal Cancer.

Authors:  Maxime Collard; Jérémie H Lefevre
Journal:  Front Oncol       Date:  2020-03-05       Impact factor: 6.244

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.